Pulse Biosciences stock (US73242P1030): Q1 2026 net loss widens to $18.6M on early commercialization

Pulse Biosciences reported Q1 2026 results with $18.6M net loss on $0.4M product revenue from initial Vybrance sales, boosted R&D spending, $68.3M cash position, and $12.9M post-quarter raise.

Pulse Biosciences announced its first-quarter 2026 financial results, posting a net loss of $18.6 million on product revenue of $0.4 million, according to its 10-Q filing as of May 2026. The wider loss from $16.8 million a year ago reflects heavy investment in R&D for nsPFA cardiac devices. Product revenue marked the start of commercialization for the Vybrance Percutaneous Electrode System.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pulse Biosciences, Inc.
• Sector/industry: Health Care Equipment & Supplies
• Headquarters/country: Miami, Florida, USA
• Core markets: Cardiac and soft-tissue ablation
• Key revenue drivers: nsPFA technology products
• Home exchange/listing venue: Nasdaq (PLSE)
• Trading currency: USD

Pulse Biosciences: core business model

Pulse Biosciences develops Nano-pulse Stimulation (NPS) technology for non-thermal cell ablation using nanosecond-duration electrical pulses. The proprietary nsPFA platform targets regulated cell death in cardiac and soft-tissue procedures without thermal damage. The company holds FDA approval for one indication and advances multiple others in clinical stages, per Bloomberg Intelligence as of 2026.

Headquartered in Miami, Florida, with operations in Hayward, California, Pulse Biosciences focuses on ablation catheters and surgical clamps. Its Vybrance system initiated commercial sales in Q1 2026, generating initial revenue amid pipeline expansion.

Main revenue and product drivers for Pulse Biosciences

Product revenue reached $0.4 million in Q1 2026 from early Vybrance Percutaneous Electrode System sales, signaling commercialization ramp-up, as detailed in the 10-Q for three months ended March 31, 2026. R&D expenses climbed to $12.6 million, prioritizing nsPFA cardiac programs, while SG&A costs hit $6.6 million.

The company ended the quarter with $68.3 million in cash and raised $12.9 million post-quarter via an at-the-market sale to its majority stockholder and CEO. Management states these funds support operations for at least one year beyond the filing date.

Industry trends and competitive position

Pulse Biosciences competes in the pulsed field ablation market, differentiating via nanosecond precision for safer, non-thermal treatments. nsPFA targets atrial fibrillation and other cardiac ablations, a segment growing with demand for minimally invasive procedures. US investors track this space for exposure to medtech innovation amid rising cardiac disease prevalence.

Why Pulse Biosciences matters for US investors

Listed on Nasdaq as PLSE, Pulse Biosciences offers US investors direct access to next-generation ablation tech. Its FDA-approved products and clinical pipeline align with US healthcare trends toward precision medicine, with potential revenue growth from cardiac device adoption in American hospitals.

Conclusion

Pulse Biosciences' Q1 2026 results highlight early revenue from Vybrance alongside elevated R&D for nsPFA expansion and a solid cash position post-raise. The company advances its ablation pipeline amid commercialization efforts. Investors monitor progress in cardiac indications and funding runway for US market relevance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.